Low circulating anti-Mullerian hormone and normal follicle stimulating hormone levels: Which prognosis in an IVF program?

被引:14
|
作者
Grzegorczyk-Martin, V. [1 ]
Khrouf, M. [1 ]
Bringer-Deutsch, S. [1 ]
Mayenga, J. -M. [1 ]
Kuski, O. [1 ]
Cohen-Bacrie, P. [2 ]
Benaim, J. -L. [3 ]
Belaisch-Allart, J. [1 ]
机构
[1] Ctr Hosp 4 Villes, Serv Gynecol Obstet & Med Reprod, F-92318 Sevres, France
[2] Lab Eylau, F-75016 Paris, France
[3] Lab Benaim, F-92140 Clamart, France
来源
GYNECOLOGIE OBSTETRIQUE & FERTILITE | 2012年 / 40卷 / 7-8期
关键词
Anti-Mullerian hormone; Follicle stimulating hormone; Ovarian response; In vitro fertilization; IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; SERUM ANTIMULLERIAN-HORMONE; POOR OVARIAN RESPONSE; INHIBIN-B; RESERVE; PREDICTION; PREGNANCY; CYCLES; MARKER;
D O I
10.1016/j.gyobfe.2012.02.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective. - To evaluate the results of controlled ovarian hyperstimulation (COH) for IVF in patients with low anti-Mullerian hormone (AMH) and normal basal follicle stimulating hormone (FSH) and Estradiol levels (<= 50 pg/mL). Patients and methods. - A retrospective cohort study including 704 patients for whom AMH and FSH levels (measured between days 3 and 5 of the menstrual cycle) were available, is performed in the IVF center at the Sevres Hospital (France). Three groups are designed and analyzed: group 1 with AMH less or equal to 2 ng/mL and FSH less or equal to 10 mUl/mL (study group), Group 2 with AMH greater than 2 ng/mL and FSH less or equal to 10 mUl/mL (control group) and Group 3 with AMH less or equal to 2 ng/mL and FSH greater than 10 mUl/mL (group with decreased ovarian reserve). Results. - IVF outcome for patients from the study group is significantly worse than that of the second but not than that of the third group. In the first group, the number of retrieved oocytes, the number of total obtained embryos, the clinical pregnancy rate and the live birth rate are significantly lower than in the second group; moreover, there are more cancelled cycles because of poor response in the first group. There is no difference with the third group. Discussion and conclusions. - This study shows that women with a low baseline AMH have a similar response to COH to the poor responders patients with a decreased ovarian reserve revealed by an elevated FSH level. Thus, when a woman undergoing IVF cycle presents a low AMH, she might be considered as a poor responder patient regardless of the FSH level and, although the clinical pregnancy rate is not so disappointing (18%), the couple should be informed of a higher risk of cycle cancellation. (c) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [41] Marker of Follicular Responsiveness to Follicle-Stimulating Hormone by Anti-Mullerian Hormone in Normo-Ovulating Women
    Scheffer, Juliano Brum
    Mendez Lozano, Daniel H.
    Frydman, Rene
    Fanchin, Renato
    JORNAL BRASILEIRO DE REPRODUCAO ASSISTIDA, 2007, 11 (02): : 9 - 13
  • [42] Age-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women
    Raeissi, Alireza
    Torki, Alireza
    Moradi, Ali
    Mousavipoor, Seyed Mehdi
    Pirani, Masoud Doosti
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2015, 9 (01) : 27 - 32
  • [43] Maternal serum concentration of anti-Mullerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment
    Sadruddin, Sheela
    Barnett, Brian
    Ku, Lowell
    Havemann, Dara
    Mucowski, Sara
    Herrington, Richard
    Burggren, Warren
    PLOS ONE, 2020, 15 (10):
  • [44] CIRCULATING ANTI-MULLERIAN HORMONE LEVELS MAY PREDICT BLASTOCYST FORMATION RATES IN DONOR IVF CYCLES.
    Gilbert, J. H.
    Settle, J. C.
    Nichols, J. E.
    Taylor, T. H.
    Wininger, J. D.
    Roudebush, W. E.
    FERTILITY AND STERILITY, 2010, 94 (04) : S265 - S265
  • [45] Ovarian cortical follicle density in infertile women with low anti-Mullerian hormone
    Lunding, Stine Aagaard
    Pors, Susanne Elisabeth
    Kristensen, Stine Gry
    Botkjaer, Jane Alro
    Ramlose, Maja
    Jeppesen, Janni Vikkelso
    Flachs, Esben Meulengracht
    Pinborg, Anja
    Macklon, Kirsten Tryde
    Pedersen, Anette Tonnes
    Andersen, Claus Yding
    Andersen, Anders Nyboe
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2020, 37 (01) : 109 - 117
  • [46] Anti-Mullerian hormone levels in girls and adolescents
    Czech, Iwona J.
    Drosdzol-Cop, Agnieszka
    GINEKOLOGIA POLSKA, 2022, 93 (09) : 756 - 760
  • [47] A case report supporting the concept that a role for the anti-Mullerian hormone (AMH) in normal folliculogenesis is to diminish the biological activity of follicle stimulating hormone (FSH)
    Check, J. H.
    Chang, E.
    Cohen, R.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2020, 47 (04): : 620 - 621
  • [48] Random anti-Mullerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
    Buyuk, Erkan
    Seifer, David B.
    Younger, Joshua
    Grazi, Richard V.
    Lieman, Harry
    FERTILITY AND STERILITY, 2011, 95 (07) : 2369 - 2372
  • [49] Age effect on in vitro fertilization pregnancy mediated by anti-Mullerian hormone (AMH) and modified by follicle stimulating hormone (FSH)
    Han-Chih Hsieh
    Jia-Ying Su
    Shunping Wang
    Yen-Tsung Huang
    BMC Pregnancy and Childbirth, 20
  • [50] Comparison of serum concentration of anti-mullerian hormone and follicle stimulating hormone with length of telomeres in women with premature ovarian insufficiency
    Pogacnik, Renata Kosir
    Slabe, Nina
    Novakovic, Srdjan
    Cerkovnik, Petra
    Vrtovec, Helena Meden
    Kodre, Anamarija Rebolj
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 109 - 109